NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $19.60.
A number of equities analysts have commented on the stock. The Goldman Sachs Group dropped their price objective on shares of NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Bank of America dropped their price target on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. Piper Sandler decreased their price objective on NeoGenomics from $21.00 to $18.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Jefferies Financial Group initiated coverage on NeoGenomics in a report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 target price for the company. Finally, Benchmark downgraded NeoGenomics from a "buy" rating to a "hold" rating in a research report on Monday, January 13th.
Check Out Our Latest Analysis on NeoGenomics
Institutional Trading of NeoGenomics
Hedge funds and other institutional investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new position in NeoGenomics in the 4th quarter worth about $26,000. Versant Capital Management Inc grew its position in shares of NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after buying an additional 1,142 shares in the last quarter. Quarry LP purchased a new stake in NeoGenomics in the third quarter worth about $40,000. Sterling Capital Management LLC boosted its stake in shares of NeoGenomics by 788.7% during the fourth quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock valued at $61,000 after purchasing an additional 3,289 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in NeoGenomics by 203.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock valued at $70,000 after acquiring an additional 2,787 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.
NeoGenomics Price Performance
Shares of NEO stock traded up $0.92 during trading hours on Friday, hitting $9.12. The stock had a trading volume of 3,219,702 shares, compared to its average volume of 922,960. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -14.71 and a beta of 1.41. NeoGenomics has a one year low of $8.05 and a one year high of $19.12. The stock's 50-day moving average price is $10.78 and its two-hundred day moving average price is $13.86.
NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.05). The firm had revenue of $172.00 million during the quarter, compared to the consensus estimate of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. Equities analysts forecast that NeoGenomics will post -0.2 EPS for the current year.
NeoGenomics Company Profile
(
Get Free ReportNeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Further Reading
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
